ATE426411T1 - Neue verwendung von erythropoietin in herzerkrankungen - Google Patents
Neue verwendung von erythropoietin in herzerkrankungenInfo
- Publication number
- ATE426411T1 ATE426411T1 AT03779949T AT03779949T ATE426411T1 AT E426411 T1 ATE426411 T1 AT E426411T1 AT 03779949 T AT03779949 T AT 03779949T AT 03779949 T AT03779949 T AT 03779949T AT E426411 T1 ATE426411 T1 AT E426411T1
- Authority
- AT
- Austria
- Prior art keywords
- erythropoietin
- heart disease
- new use
- new
- heart
- Prior art date
Links
- 102000003951 Erythropoietin Human genes 0.000 title 1
- 108090000394 Erythropoietin Proteins 0.000 title 1
- 229940105423 erythropoietin Drugs 0.000 title 1
- 208000019622 heart disease Diseases 0.000 title 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02026342 | 2002-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE426411T1 true ATE426411T1 (de) | 2009-04-15 |
Family
ID=32337998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03779949T ATE426411T1 (de) | 2002-11-22 | 2003-11-17 | Neue verwendung von erythropoietin in herzerkrankungen |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7459436B2 (de) |
| EP (1) | EP1565206B1 (de) |
| JP (1) | JP2006512326A (de) |
| KR (1) | KR100839302B1 (de) |
| CN (1) | CN100531797C (de) |
| AR (1) | AR042097A1 (de) |
| AT (1) | ATE426411T1 (de) |
| AU (1) | AU2003288081B2 (de) |
| BR (1) | BRPI0316438C1 (de) |
| CA (1) | CA2505524C (de) |
| DE (1) | DE60326874D1 (de) |
| ES (1) | ES2321928T3 (de) |
| MX (1) | MXPA05005281A (de) |
| PL (1) | PL210256B1 (de) |
| RU (1) | RU2324494C2 (de) |
| WO (1) | WO2004047858A1 (de) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| PL1615945T3 (pl) | 2003-04-09 | 2012-03-30 | Ratiopharm Gmbh | Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami |
| US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| NZ592039A (en) * | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| SI1696947T1 (sl) * | 2003-12-19 | 2014-05-30 | F. Hoffmann-La Roche Ag | Uporaba eritropoetina pri zdravljenju motenj porazdelitve železa pri kroničnih vnetnih črevesnih boleznih |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| EP1929860A4 (de) * | 2005-08-31 | 2010-12-29 | Kaneka Corp | Transgener vogel mit fremdgen enthaltend eine sequenz, die für ein von der katze abstammendes protein codiert, sowie verfahren zu seiner herstellung |
| US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US8304386B2 (en) * | 2006-02-03 | 2012-11-06 | Prolor Biotech, Inc. | Long-acting growth hormone and methods of producing same |
| US7553941B2 (en) | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US8476234B2 (en) * | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
| EP2049144B8 (de) | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylierung von peptiden über o-verbundene glycosylierungssequenzen |
| EP2054521A4 (de) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | Verfahren zur reinigung von polypeptid-konjugate |
| HRP20130382T1 (hr) | 2007-04-03 | 2013-05-31 | Biogenerix Ag | Postupci lijeäśenja pomoä†u glikopegiliranog g-csf |
| CA2690611C (en) | 2007-06-12 | 2015-12-08 | Novo Nordisk A/S | Improved process for the production of nucleotide sugars |
| PL2257311T3 (pl) | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Koniugaty cząsteczek czynnika VIII |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| CN101870735B (zh) * | 2010-06-02 | 2013-06-12 | 北京精益泰翔技术发展有限公司 | 一种新型高糖基化促红细胞生成素免疫融合蛋白 |
| HK1207564A1 (en) | 2012-04-19 | 2016-02-05 | Opko Biologics Ltd | Long-acting oxyntomodulin variants and methods of producing same |
| HUE055348T2 (hu) | 2012-11-20 | 2021-11-29 | Opko Biologics Ltd | Eljárás polipeptidek hidrodinamikus térfogatának növelésére gonadotropin karboxil-terminális peptidekhez való kapcsolással |
| DK4374873T3 (da) | 2013-07-12 | 2025-11-03 | Astellas Us Llc | Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| EP3230309B1 (de) | 2014-12-10 | 2023-03-29 | OPKO Biologics Ltd. | Verfahren zur herstellung langwirkender ctp-modifizierter wachstumshormonpolypeptide |
| PL3310347T3 (pl) | 2015-06-19 | 2021-12-27 | Opko Biologics Ltd. | Długo działające czynniki krzepnięcia i sposoby wytwarzania |
| MY206271A (en) | 2016-07-11 | 2024-12-06 | Opko Biologics Ltd | Long-acting coagulation factor vii and methods of producing same |
| US20230331798A1 (en) * | 2020-09-22 | 2023-10-19 | Jecho Laboratories, Inc. | Glycosylation-modified erythopoietin and use thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS57183508A (en) * | 1981-05-07 | 1982-11-11 | Nippon Piston Ring Co Ltd | Compound valve seat |
| IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
| US4745099A (en) * | 1985-02-06 | 1988-05-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of malignant tumors |
| NO881507D0 (no) | 1987-04-10 | 1988-04-07 | Ortho Pharma Corp | Fremgangsmaate for forhoeyning av hematokritnivaaet til et normalt pattedyr. |
| FR2646438B1 (fr) * | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| DE3924705A1 (de) | 1989-07-26 | 1991-01-31 | Boehringer Mannheim Gmbh | Heterobifunktionelle verbindungen |
| EP0945515A3 (de) | 1989-11-06 | 2002-08-21 | Cell Genesys, Inc. | Herstellung von Proteinen mittels homologer Rekombination |
| ES2151463T5 (es) | 1989-12-22 | 2012-10-29 | Merck Serono Sa | Constructos de ADN para la activación y la modificación de la expresión de genes endógenos |
| US5272071A (en) * | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| GB9001987D0 (en) * | 1990-01-29 | 1990-03-28 | Janssen Pharmaceutica Nv | Improved cyclodextrin based erythropietin formulation |
| US5324650A (en) * | 1990-03-20 | 1994-06-28 | E. I. Du Pont De Nemours And Company | Situ process for production of conjugates |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| JPH06506217A (ja) | 1991-03-18 | 1994-07-14 | エンゾン，インコーポレーテッド | ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体 |
| NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
| PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
| US5641670A (en) * | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5733761A (en) * | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
| CA2101361A1 (en) | 1992-08-27 | 1994-02-28 | Robert A. Snow | Low diol polyalkylene oxide biologically active proteinaceous substances |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| CN1057534C (zh) | 1993-08-17 | 2000-10-18 | 柯瑞英-艾格公司 | 促红细胞生成素类似物 |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| RU2089214C1 (ru) * | 1994-01-06 | 1997-09-10 | Научно-исследовательский центр Санкт-Петербургского медицинского института им.акад.И.П.Павлова | Средство для снижения патологической проницаемости сосудов к белкам |
| US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| DE19535571A1 (de) * | 1995-09-14 | 1997-03-20 | Boehringer Mannheim Gmbh | Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten |
| WO1998032466A1 (en) | 1997-01-29 | 1998-07-30 | Polymasc Pharmaceuticals Plc | Pegylation process |
| IL131959A0 (en) | 1997-03-18 | 2001-03-19 | Roche Diagnostics Gmbh | Pharmaceutical combined preparations containing erythropoietin and iron preparations |
| EP0885613A1 (de) * | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
| DE19734293A1 (de) * | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen |
| JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| ME00673B (me) | 2000-05-15 | 2011-12-20 | Hoffmann La Roche | Nova farmaceutska smjesa |
| US7078376B1 (en) * | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| US20020065214A1 (en) * | 2000-11-29 | 2002-05-30 | Adrian Iaina | Method of treating congestive heart failure |
| AU2002233230B2 (en) * | 2000-12-20 | 2007-02-01 | F. Hoffmann-La Roche Ag | Erythropoietin conjugates |
| EP1425589B1 (de) | 2001-09-14 | 2007-12-05 | F. Hoffmann-La Roche Ag | Differentialdiagnose von störungen vom eisenmetabolismus |
-
2003
- 2003-11-12 US US10/706,701 patent/US7459436B2/en not_active Expired - Lifetime
- 2003-11-17 WO PCT/EP2003/012822 patent/WO2004047858A1/en not_active Ceased
- 2003-11-17 CN CNB2003801038773A patent/CN100531797C/zh not_active Expired - Lifetime
- 2003-11-17 MX MXPA05005281A patent/MXPA05005281A/es active IP Right Grant
- 2003-11-17 RU RU2005119649/15A patent/RU2324494C2/ru active
- 2003-11-17 PL PL377590A patent/PL210256B1/pl unknown
- 2003-11-17 AU AU2003288081A patent/AU2003288081B2/en not_active Expired
- 2003-11-17 EP EP03779949A patent/EP1565206B1/de not_active Expired - Lifetime
- 2003-11-17 ES ES03779949T patent/ES2321928T3/es not_active Expired - Lifetime
- 2003-11-17 KR KR1020057009185A patent/KR100839302B1/ko not_active Expired - Lifetime
- 2003-11-17 AT AT03779949T patent/ATE426411T1/de active
- 2003-11-17 CA CA2505524A patent/CA2505524C/en not_active Expired - Lifetime
- 2003-11-17 BR BRPI0316438A patent/BRPI0316438C1/pt not_active IP Right Cessation
- 2003-11-17 JP JP2004554368A patent/JP2006512326A/ja active Pending
- 2003-11-17 DE DE60326874T patent/DE60326874D1/de not_active Expired - Lifetime
- 2003-11-20 AR ARP030104288A patent/AR042097A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR100839302B1 (ko) | 2008-06-17 |
| RU2324494C2 (ru) | 2008-05-20 |
| DE60326874D1 (de) | 2009-05-07 |
| BRPI0316438C1 (pt) | 2021-05-25 |
| CN1713919A (zh) | 2005-12-28 |
| US20040209802A1 (en) | 2004-10-21 |
| AR042097A1 (es) | 2005-06-08 |
| WO2004047858A1 (en) | 2004-06-10 |
| EP1565206A1 (de) | 2005-08-24 |
| CA2505524C (en) | 2017-02-07 |
| BRPI0316438B1 (pt) | 2016-08-02 |
| PL210256B1 (pl) | 2011-12-30 |
| AU2003288081B2 (en) | 2007-02-01 |
| MXPA05005281A (es) | 2005-07-25 |
| RU2005119649A (ru) | 2006-03-20 |
| BRPI0316438B8 (pt) | 2016-09-27 |
| ES2321928T3 (es) | 2009-06-15 |
| JP2006512326A (ja) | 2006-04-13 |
| BR0316438A (pt) | 2005-10-11 |
| US7459436B2 (en) | 2008-12-02 |
| EP1565206B1 (de) | 2009-03-25 |
| AU2003288081A1 (en) | 2004-06-18 |
| CA2505524A1 (en) | 2004-06-10 |
| PL377590A1 (pl) | 2006-02-06 |
| CN100531797C (zh) | 2009-08-26 |
| KR20050085091A (ko) | 2005-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE426411T1 (de) | Neue verwendung von erythropoietin in herzerkrankungen | |
| DE60334277D1 (de) | Verwendung von Algenproteinen in Kosmetika | |
| ATE510556T1 (de) | Verwendung von erythropoietin | |
| ATE365719T1 (de) | O-cyclopropyl-carboxanilide und ihre verwendung als fungizide | |
| DE60216275D1 (de) | Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit | |
| DE502005006470D1 (de) | Verwendung von sulfonylharnstoffen | |
| DE50306850D1 (de) | Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen | |
| DE60318920D1 (de) | Induktion von Insulin-produzierende Zellen | |
| EP1674473A4 (de) | Generator von photosäure | |
| DE60325967D1 (de) | Stimulierung von hämatopoiese bei ex vivo aktivierten immunzellen | |
| FR2843963B1 (fr) | Nouvelles molecules derivees de la noraporphine | |
| DE60221143D1 (de) | Brusteinlage enthaltend hautpflegemittel | |
| DE602004027637D1 (de) | Verwendung von cupredoxin-proteine für krebstherapie | |
| EP1499186A4 (de) | Verwendung von häm-oxygenase-1 und häm-abbauprodukte | |
| ATE491814T1 (de) | Herstellung von titanoxid | |
| FI20031453L (fi) | Järjestely ja menetelmä tiedon tarjoamiseksi käyttäjälle | |
| ATE275390T1 (de) | Verwendung von kationischen zubereitungen | |
| DE602004004262D1 (de) | Ultraschallbehandlung von gewebematrices | |
| EP1924684A4 (de) | Übergangszustandsstruktur von 5'-methylthioadenosin/s-adenosylhomocystein-nukleosidasen | |
| DE60318819D1 (de) | Hitzestabile mutanten von stärkebiosyntheseenzymen | |
| DE60327084D1 (de) | Verwendung von n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3-sulphonamid in der tumortherapie | |
| DE50304051D1 (de) | Verwendung von kunststofffolien als dielektrikum in kondensatoren | |
| DE60324586D1 (de) | Substituierte pyridyloxyalkylamide und ihre verwendung als fungizide | |
| DE50311406D1 (de) | Verwendung von Formkörpern | |
| DE60217870D1 (de) | Verwendung von 2- 5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1565206 Country of ref document: EP |